Overview

CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: CC-4047 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of CC-4047 in treating patients with advanced solid tumors that did not respond to treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Case Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Pomalidomide
Thalidomide